

Dear Editors of World Journal of Hepatology,

Thank you for reviewing our manuscript entitled, "Metabolic Syndrome Does Not Affect Sustained Virologic Response of Direct-Acting Antivirals while Hepatitis C Clearance Improves Hemoglobin A1c." (Manuscript ID: 39254). Please find below our responses to the reviewers' comments.

Reviewer #1: In this retrospective study, a total of 1068 patients were treated with DAA were enrolled, successful treatment with DAA was associated with a significant reduction in HbA1c in HCV patients with T2DM, suggesting that DAA may have a role in improving insulin sensitivity. Furthermore, unlike prior studies during the period of pegylated-interferon, metabolic syndrome does not negatively affect SVR12 rates for DAA. These results may help elucidate the relationship between HCV, insulin sensitivity, and longer-term DM outcomes such as cardiovascular events.

Response: Thank you for the kind comments. We agree that these results will help elucidate the relationship between HCV and DM.

Reviewer #2: This study is interesting and has clinical significance. I recommend it to be published. 2. From the paper, we can see that several DAA drugs have been used in the patients, I suggest that this should be mentioned in the Abstract.

Response: Thank you for the kind comments. We have made small edit in the abstract to highlight the fact that several DAA were analyzed in this study.

Sincerely,



Tien Dong, MD
10945 Le Conte Ave
PVUB 2114 MC694907
Los Angeles, CA, 90095
Email: tsdong@mednet.ucla.edu